K-State licenses technology for coronavirus, norovirus compoundsMarch 2, 2020As global concerns surrounding the novel coronavirus COVID-19 continue to escalate, Kansas State University (K-State) has licensed a technology it says might lead to the production of an antiviral drug treatment.
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started